Abstract
This Viewpoint considers the merits of e-cigarettes as a harm-minimisation tool for clozapine-treated schizophrenia patients. It argues that e-cigarettes may be a gateway not to smoking tobacco, but rather to engagement in more desirable health attitudes amongst this particularly marginalised population group. In our opinion, this presents clinicians with valuable opportunities to engage their patients more effectively in healthcare strategies, beginning with but not limited to tobacco-free e-cigarettes.
Original language | English |
---|---|
Pages (from-to) | 170-171 |
Number of pages | 2 |
Journal | International Journal of Drug Policy |
Volume | 73 |
DOIs | |
Publication status | Published - Nov 2019 |
Keywords
- E-cigarettes
- Harm reduction
- Health agency
- Schizophrenia
- Tobacco control